12/18/2009

Merck & Co. will acquire Avecia Biologics to gain access to the U.K. company's drug-development technology that uses bacteria and yeast cells. The deal is expected to strengthen Merck's biotech-drug business, which includes biotech-molecule manufacturer GlycoFi.

Related Summaries